On-Demand Webinar: Characterizing Anti-HER2 Antibodies with Advanced Flow Cytometry & BLI Label-Free Detection


Antibody-based therapeutics are helping patients across a wide range of disease areas, from cancer, such as Rituximab treatment of CD20-positive non-Hodgkin's lymphomas, to infectious diseases like SARS-CoV-2 and HIV. Conventional techniques used in antibody discovery workflows are often limited due to low-throughput sample acquisition, large sample volume requirements, and challenges around analyzing complex datasets. The development of novel antibody therapeutics relies on high-throughput technologies with powerful analysis capabilities that can reliably screen and profile drug candidates.

  • Document type: Webinar
  • Watch time: 41 minutes

View to Watch On-Demand

View This Webinar to Learn About:

  • Combining the iQue® Advanced Flow Cytometry and Octet® BLI Label-Free Detection platforms to characterize antibodies during drug discovery
  • Using the iQue® and associated reagent kits for high-throughput analysis of live-cell antibody binding, competitive binding, and Fc function
  • Determination of ligand and Fc-gamma receptor binding kinetics through robust measurements with the Octet® system

Webinar Speaker

Kirsty McBain

Scientist, BioAnalytics


Kirsty McBain is a Scientist in the BioAnalytics applications group at Sartorius where she is involved in research and development of novel applications for the iQue® advanced flow cytometry platform.

She has supported a number of the immuno-oncology campaigns that are used to exemplify how Sartorius technology can be applied to the drug discovery process. Kirsty obtained a master’s degree in Biochemistry at the University of Bristol before joining Sartorius in 2019.

David Apiyo, Ph.D.

Senior Manager, Applications


David is a Senior Manager of Applications at Sartorius, focused on Octet label-free detection platforms and applications. In this role, he leads a team of Applications Managers and is responsible for the strategic direction of the GMP/GxP and bioprocessing vertical markets.

David started out as a Field Applications Scientist in 2011 and transitioned to the marketing applications team in 2015. Prior to this, David worked as a Senior Development Scientist, R&D department, at Beckman Coulter where he was involved in the development and validation of protein and antibody conjugate chemistries. 

David obtained his Ph.D. in Protein Chemistry from Tulane University, New Orleans.

Request a Quote, Demo, or More Information

What other areas are you interested in? (select all that apply)

Complete the Form Below to Watch the On-Demand Webinar